Results 81 to 90 of about 392,226 (299)

Molecular cancer prevention: Intercepting disease

open access: yesMolecular Oncology, EarlyView.
Oncological practice must evolve, from treating established tumours to proactive cancer interception before clinical manifestation. This will require mechanistic insight into tumour initiation, validated biomarkers of early disease development and redesigned clinical trials, enabling cancer interception to become a core pillar of oncology with the ...
Charlotte Grieco   +2 more
wiley   +1 more source

Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]

open access: yes, 2011
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van   +3 more
core   +1 more source

Gaps in Treatment and Surveillance: Head and Neck Cancer Care in a Safety-Net Hospital. [PDF]

open access: yes, 2020
Objective:Treatment delays and suboptimal adherence to posttreatment surveillance may adversely affect head and neck cancer (HNC) outcomes. Such challenges can be exacerbated in safety-net settings that struggle with limited resources and serve a ...
Brodie, Shauna   +7 more
core   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

open access: yesFEBS Open Bio, EarlyView.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold   +11 more
wiley   +1 more source

PB2114: TREATMENT RESULTS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FROM HIGH-RISK GROUP

open access: yesHemaSphere, 2022
K. Filonenko   +12 more
doaj   +1 more source

A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. [PDF]

open access: yes, 2015
Hepatocellular carcinoma (HCC), the second leading cause of cancer deaths worldwide, is difficult to treat and highly lethal. Since HCC is predominantly diagnosed in patients with cirrhosis, treatment planning must consider both the severity of liver ...
Busuttil, Ronald W   +2 more
core   +2 more sources

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

open access: yesFEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani   +6 more
wiley   +1 more source

Prognostic nutritional index before adjuvant chemotherapy predicts chemotherapy compliance and survival among patients with non-small-cell lung cancer

open access: yesTherapeutics and Clinical Risk Management, 2015
Katsuhiko Shimizu, Riki Okita, Shinsuke Saisho, Takuro Yukawa, Ai Maeda, Yuji Nojima, Masao Nakata Department of General Thoracic Surgery, Kawasaki Medical School, Kurashiki, Japan Background: Adjuvant chemotherapy after the complete resection of non ...
Shimizu K   +6 more
doaj  

Effectiveness of postoperative radiotherapy after radical cystectomy for locally advanced bladder cancer [PDF]

open access: yes, 2019
BACKGROUND: Local-regional failure (LF) for locally advanced bladder cancer (LABC) after radical cystectomy (RC) is common even with chemotherapy and is associated with high morbidity/mortality.
Andriole, Gerald L   +15 more
core   +2 more sources

Tumor markers in breast cancer - European Group on Tumor Markers recommendations [PDF]

open access: yes, 2005
Recommendations are presented for the routine clinical use of serum and tissue-based markers in the diagnosis and management of patients with breast cancer.
Abraha RS   +136 more
core   +1 more source

Home - About - Disclaimer - Privacy